[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 1514 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
H. RES. 1514

               Raising awareness for the cancer chordoma.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            December 8, 2022

   Mr. Johnson of Georgia (for himself, Mr. Higgins of New York, Mr. 
Fitzpatrick, Mr. Kilmer, Mr. Thompson of Mississippi, and Ms. Williams 
 of Georgia) submitted the following resolution; which was referred to 
                  the Committee on Energy and Commerce

_______________________________________________________________________

                               RESOLUTION


 
               Raising awareness for the cancer chordoma.

Whereas chordoma is a slow growing, yet aggressive bone cancer of the skull and 
        spine;
Whereas it strikes people of all ages and affects more than 25,000 individuals 
        worldwide;
Whereas each year, thousands of people are diagnosed with chordoma including 
        about 300 people annually in the United States;
Whereas chordomas are among the most complicated tumors to treat due to 
        involvement of critical structures such as the brain stem, spinal cord, 
        and important nerves and arteries;
Whereas surgery or radiation performed by a skilled treatment team can be 
        curative for some patients, but even with the best care possible, the 
        recurrence rate remains high; and
Whereas no drugs are known to cure or effectively control the disease, meaning 
        that patients whose disease progresses after exhausting surgical and 
        radiation options have little hope for a full recovery: Now, therefore, 
        be it
    Resolved, That it is the sense of the House of Representatives that 
chordoma patients and families need increased funding and support for--
            (1) accurate and early diagnosis;
            (2) the development of new treatments, diagnostics, and 
        cures;
            (3) fewer hurdles between research and new treatments; and
            (4) patient-centric approaches to drug discovery and 
        development.
                                 <all>